Promising Developments and Strategic Collaborations Bolster Buy Rating for Olema Pharmaceuticals
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...
All in the blood: New way to detect drug resistance in ovarian cancer patients
Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...